KEY DETAILS
Researchers at the Wharton School of the University of Pennsylvania are conducting a study to determine whether GLP-1 drugs can reduce risky financial decisions such as gambling and compulsive shopping, CBS News reported on October 8, 2026.
The New York Post reported on October 8, 2026 that people on GLP-1 drugs were nearly 25% more likely to experience a nail disorder, and 39% of users reported nail detachment compared with 9% of controls.
BuzzFeed, on October 7, 2026, featured accounts from 39 people describing emotional and psychological side effects of GLP-1 medications that receive little public attention.
A study linking Ozempic and Wegovy to a lower Alzheimer's risk in people with type 2 diabetes was already reported in an earlier edition, so this is not new.
Nutritionists' warning that 'GLP-1-friendly' food labels can be misleading was already covered in an earlier edition.
Researchers at the Wharton School of the University of Pennsylvania are planning a study of whether GLP-1 drugs can curb more than appetite, looking at whether they might also reduce compulsive shopping and gambling. That question sits alongside other recent reports on what these drugs may do beyond weight loss, from nail changes to emotional side effects that users describe as getting little public attention.
CBS News reported on October 8, 2026 that the Wharton researchers will explore whether GLP-1 drugs can deter risky or impulsive financial decisions, including gambling and compulsive shopping. The study will recruit about 180 participants and run from mid-October through around March 2027, using MRI scans to monitor how participants' brain reward systems respond to financial and food-related stimuli. One neuroscientist said the effect "might be very good financially for the average person." The study has not yet produced results, so there is no evidence yet on whether GLP-1 drugs change spending or gambling behavior.
A separate study, reported by the New York Post on October 8, 2026, found a link between GLP-1 use and changes in nails. People on GLP-1 drugs were nearly 25% more likely to experience a nail disorder than those not on the drugs. The outlet also reported that 39% of GLP-1 users reported nail detachment, compared with 9% of controls, and that roughly 29 million Americans are on a GLP-1 weight loss medication.
BuzzFeed published accounts on October 7, 2026 from 39 people describing emotional and psychological side effects of GLP-1 medications. The outlet said these effects often go unnoticed but significantly affect users' lives. Some users described losing the ability to use food as a way to manage difficult feelings. These are personal accounts shared with the outlet, not study results.
The Alzheimer's connection is not new. Fortune reported on October 7, 2026 on a study in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, which found that patients with type 2 diabetes who were prescribed semaglutide had a 40% to 70% reduced risk of a first-time Alzheimer's diagnosis compared with those prescribed other antidiabetic medications. The study did not examine people without diabetes. This was covered in an earlier edition, and nothing new has been added here.
The same holds for warnings from nutritionists about food labels marketed as GLP-1 friendly, which delish.com reported on October 7, 2026 and which were covered in an earlier edition. Delish reported that neither the FDA nor the USDA has defined what the term means on food labels. Nothing new has been added to that report here.
The stories in this edition show researchers and users looking at GLP-1 drugs well beyond weight loss. The nail findings come from a reported study, the accounts of emotional side effects are personal experiences, and the research on compulsive spending and gambling has not yet produced results. The Wharton study is expected to run through around March 2027.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.